JP2013517330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517330A5 JP2013517330A5 JP2012550125A JP2012550125A JP2013517330A5 JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5 JP 2012550125 A JP2012550125 A JP 2012550125A JP 2012550125 A JP2012550125 A JP 2012550125A JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 74
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims description 35
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 30
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29679110P | 2010-01-20 | 2010-01-20 | |
| US61/296,791 | 2010-01-20 | ||
| PCT/US2011/021939 WO2011091177A1 (en) | 2010-01-20 | 2011-01-20 | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517330A JP2013517330A (ja) | 2013-05-16 |
| JP2013517330A5 true JP2013517330A5 (enExample) | 2014-03-06 |
Family
ID=44307212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550125A Pending JP2013517330A (ja) | 2010-01-20 | 2011-01-20 | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9023997B2 (enExample) |
| EP (1) | EP2525813B1 (enExample) |
| JP (1) | JP2013517330A (enExample) |
| AU (1) | AU2011207253B2 (enExample) |
| CA (1) | CA2787783A1 (enExample) |
| WO (1) | WO2011091177A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2525822B1 (en) * | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| US10097315B2 (en) * | 2013-04-19 | 2018-10-09 | Qualcomm Incorporated | Group scheduling and acknowledgement for wireless transmission |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| US9985802B2 (en) * | 2014-10-31 | 2018-05-29 | Qualcomm Incorporated | Channel estimation enhancements |
| AU2016218900A1 (en) * | 2015-02-11 | 2017-08-24 | University Health Network | Methods and compositions for modulating LILR proteins |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| CA3047833A1 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| AU2019302454A1 (en) | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| JP7631203B2 (ja) * | 2019-01-18 | 2025-02-18 | ユニバーシティ ヘルス ネットワーク | Ｌｉｌｒｂ３結合分子とその使用 |
| US20220233638A1 (en) * | 2019-03-28 | 2022-07-28 | Waseda University | Cell competition inhibitor |
| WO2021160838A1 (en) * | 2020-02-12 | 2021-08-19 | Bioinvent International Ab | Lilrb3 antibody molecules and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61122292A (ja) | 1984-11-16 | 1986-06-10 | Teijin Ltd | 新規カルバサイクリン中間体の製法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DK0614984T4 (da) | 1993-03-05 | 2010-12-20 | Bayer Healthcare Llc | Humane monoklonale anti-TNF-alfa-antistoffer |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| IL127127A0 (en) * | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| CA2398251A1 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides |
| AU2001239955A1 (en) | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel macrophage nucleic acids and polypeptides |
| JP2004501624A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003041650A2 (en) * | 2001-11-14 | 2003-05-22 | Immunex Corporation | Modulation of lir function to treat rheumatoid arthritis |
| WO2003051834A2 (en) | 2001-12-14 | 2003-06-26 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders |
| NZ543960A (en) * | 2003-05-09 | 2008-11-28 | Univ Duke | CD20-specific antibodies and methods of employing same |
| CA2606576A1 (en) * | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | High-level expression of recombinant antibody in a mammalian host cell |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| SG163615A1 (en) | 2005-07-11 | 2010-08-30 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| WO2007092165A2 (en) | 2006-01-23 | 2007-08-16 | President And Fellows Of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| TW200815470A (en) | 2006-03-30 | 2008-04-01 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| EP2037961B1 (en) | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR20090082480A (ko) | 2006-11-14 | 2009-07-30 | 제넨테크, 인크. | 뉴런 재생의 조절인자 |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US8715941B2 (en) | 2007-11-16 | 2014-05-06 | Arca Biopharma, Inc. | Antibodies to LRP6 |
| AU2008335245A1 (en) * | 2007-12-11 | 2009-06-18 | Genentech, Inc. | Modulators of neuronal regeneration |
| US20090285803A1 (en) | 2008-05-13 | 2009-11-19 | Jasvinder Atwal | ANTI-PirB ANTIBODIES |
| CN102089327A (zh) | 2008-05-13 | 2011-06-08 | 健泰科生物技术公司 | 抗PirB抗体 |
| WO2010005519A1 (en) | 2008-06-30 | 2010-01-14 | University Of Pennsylvania | Fn14/trail fusion proteins |
| CN102421913A (zh) | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| WO2012061620A1 (en) | 2010-11-04 | 2012-05-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| AR086287A1 (es) | 2011-05-05 | 2013-12-04 | Baylor Res Inst | Composicion inmunoestimulante, metodo |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
-
2011
- 2011-01-20 CA CA2787783A patent/CA2787783A1/en not_active Abandoned
- 2011-01-20 JP JP2012550125A patent/JP2013517330A/ja active Pending
- 2011-01-20 US US13/574,307 patent/US9023997B2/en active Active
- 2011-01-20 EP EP11735199.9A patent/EP2525813B1/en not_active Not-in-force
- 2011-01-20 WO PCT/US2011/021939 patent/WO2011091177A1/en not_active Ceased
- 2011-01-20 AU AU2011207253A patent/AU2011207253B2/en not_active Ceased
-
2015
- 2015-03-11 US US14/644,229 patent/US9828425B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517330A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2020180158A5 (enExample) | ||
| JP2021191763A5 (enExample) | ||
| JP2012502649A5 (enExample) | ||
| JP2020039360A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| JP2020055849A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2010513539A5 (enExample) | ||
| JP2018512379A5 (enExample) | ||
| JP2016507523A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2010538608A5 (enExample) | ||
| JP2011517447A5 (enExample) | ||
| JP2011519571A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2014503205A5 (enExample) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2014526898A5 (enExample) | ||
| JP2021101720A5 (enExample) |